Literature DB >> 27779774

Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma.

Hui Yu1, Elena Sotillo2, Colleen Harrington2,3, Gerald Wertheim1, Michele Paessler1, Shannon L Maude4,5, Susan R Rheingold4,5, Stephan A Grupp4,5, Andrei Thomas-Tikhonenko1,2,3, Vinodh Pillai1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27779774     DOI： 10.1002/ajh.24594

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  30 in total

Review 1.  Chimeric antigen receptor T cell therapies for acute myeloid leukemia.

Authors:  Bin Gu; Jianhong Chu; Depei Wu
Journal:  Front Med       Date:  2020-12-01       Impact factor: 4.592

Review 2.  Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors.

Authors:  Sisi Zheng; Mukta Asnani; Andrei Thomas-Tikhonenko
Journal:  Cancer J       Date:  2019 May/Jun       Impact factor: 3.360

3.  Targeting CD19: the good, the bad, and CD81.

Authors:  Mireya Paulina Velasquez; Stephen Gottschalk
Journal:  Blood       Date:  2017-01-05       Impact factor: 22.113

Review 4.  Mechanisms of resistance to CAR T cell therapy.

Authors:  Nirali N Shah; Terry J Fry
Journal:  Nat Rev Clin Oncol       Date:  2019-06       Impact factor: 66.675

Review 5.  The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.

Authors:  Peter Braendstrup; Bruce L Levine; Marco Ruella
Journal:  Cytotherapy       Date:  2020-02-01       Impact factor: 5.414

6.  Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML.

Authors:  Fabiana Perna; Samuel H Berman; Rajesh K Soni; Jorge Mansilla-Soto; Justin Eyquem; Mohamad Hamieh; Ronald C Hendrickson; Cameron W Brennan; Michel Sadelain
Journal:  Cancer Cell       Date:  2017-10-09       Impact factor: 31.743

7.  Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma.

Authors:  Haneen Shalabi; Ira L Kraft; Hao-Wei Wang; Constance M Yuan; Bonnie Yates; Cindy Delbrook; Julie D Zimbelman; Roger Giller; Maryalice Stetler-Stevenson; Elaine S Jaffe; Daniel W Lee; Jack F Shern; Terry J Fry; Nirali N Shah
Journal:  Haematologica       Date:  2018-02-01       Impact factor: 9.941

8.  CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.

Authors:  Vinodh Pillai; Kavitha Muralidharan; Wenzhao Meng; Asen Bagashev; Derek A Oldridge; Jaclyn Rosenthal; John Van Arnam; Jos J Melenhorst; Diwakar Mohan; Amanda M DiNofia; Minjie Luo; Sindhu Cherian; Jonathan R Fromm; Gerald Wertheim; Andrei Thomas-Tikhonenko; Michele Paessler; Carl H June; Eline T Luning Prak; Vijay G Bhoj; Stephan A Grupp; Shannon L Maude; Susan R Rheingold
Journal:  Blood Adv       Date:  2019-11-26

Review 9.  The Principles of Engineering Immune Cells to Treat Cancer.

Authors:  Wendell A Lim; Carl H June
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

Review 10.  Clinical lessons learned from the first leg of the CAR T cell journey.

Authors:  Robbie G Majzner; Crystal L Mackall
Journal:  Nat Med       Date:  2019-09-09       Impact factor: 53.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.